| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.07 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.07 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.07 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.063 | 0.07 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.092 | 0.07 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | 0.094 | 0.07 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | -0.085 | 0.07 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.08 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.081 | 0.08 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.06 | 0.08 |